shopping cart Your cart is empty
  • Home
  • Market Research
  • Non-Alcoholic Steatohepatitis Market By Drug Type (Obeticholic Acid, Aramchol, Saroglitazar, Elafibranor) - Growth, Future Prospec...

Non-Alcoholic Steatohepatitis Market By Drug Type (Obeticholic Acid, Aramchol, Saroglitazar, Elafibranor) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Published By: Brisk Insights | Published On: Jun 1, 2022

 

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases.

 

The report titled “Global Nonalcoholic Steatohepatitis Market- Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the Nonalcoholic Steatohepatitis market along with the market size and estimates for the duration 2017 to 2025. The research study covers in-depth analysis of market segments based on drug type, and different geographical region.

 

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global Nonalcoholic Steatohepatitis market, attractive investment proposition and market positioning of key manufacturers sections.

 

Geographically, the global Nonalcoholic Steatohepatitis market is studied for the following regional markets:

 

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of MEA

 

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

 

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as pipeline analysis, market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Nonalcoholic Steatohepatitis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Nonalcoholic Steatohepatitis market. This report concludes with company profiles section that highlights major information about the key players engaged in global Nonalcoholic Steatohepatitis market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report. 

 

Thus, the research study provides a holistic view of the global Nonalcoholic Steatohepatitis market, offering market size and estimates for the period from 2017 to 2025, keeping in mind the above-mentioned factors.

 

Based on the type of Drug, the Nonalcoholic Steatohepatitis market is segmented into:

 

  • Obeticholic Acid
  • Aramchol
  • Saroglitazar
  • Elafibranor

 

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. NASH affects around 2-5% of Americans and is considered to be one of the foremost causes of liver transplantation. Currently management of NASH includes lifestyle changes such as healthy diet, weight reduction and physical activity. Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials. The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.

 

For the purpose of this study, the global non-alcoholic steatohepatitis market is categorized as follows:

 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

For the purpose of this study, the global non-alcoholic steatohepatitis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. According to the British Liver Trust, Non-Alcoholic Fatty Liver Disease (NAFLD) is considered to be the most common liver problem in the Western world, affecting 20-30% of the population. North America held the largest share in the global non-alcoholic steatohepatitis market. In U.S. more than 25% of the population is affected by NAFLD as mentioned by the America Liver Foundation. Moreover, the rate of obesity is increasing rapidly in the children and adult in the U.S. which is a primary risk factor for NASH. Furthermore, aggressive research and clinical trials in the region would further boost the non-alcoholic steatohepatitis market. Asia Pacific is one of the fastest growing NASH market due to alarming increase in the obesity rates in the region due to rising lifestyle changes. Moreover, the increasing number of research & development and supportive regulations are favouring the growth of non-alcohol steatohepatitis market.

 

Chapter 1 Preface


1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

 

Chapter 2 Executive Summary


2.1 Non-Alcoholic Steatohepatitis Market Portraiture
2.2 Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016 (US$ Mn)
2.3 Non-Alcoholic Steatohepatitis Market, by Geography, 2016 (Value %)

 

Chapter 3 Global Non-Alcoholic Steatohepatitis Market Analysis


3.1 Global Non-Alcoholic Steatohepatitis Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Lucrative Pipeline for NASH Therapeutics
3.2.1.2 Alarming rise in the diabetic and Obese Population Globally
3.2.2 Challenges
3.2.2.1 High Prices of the drug considering the long duration of the treatment
3.2.2.2 Minimum Diagnostic Techniques for NASH
3.2.3 Opportunities
3.2.3.1 NASH Biomarker Development
3.3 Attractive Investment Proposition
3.4 Competitive Analysis: Global Non-Alcoholic Steatohepatitis Market, 2016 (Value %)

 

Chapter 4 Global Non-Alcoholic Steatohepatitis Market Analysis, By Drug Type


4.1 Overview
4.1.1 Market Attractive Proposition of Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016
4.2 Obeticholic Acid
4.3 Aramchol
4.4 Saroglitazar
4.5 Elafibranor

 

Chapter 5 Global Non-Alcoholic Steatohepatitis Market, By Geography


5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015-2025 (US$ Mn)
5.4 Asia-Pacific (China, Japan & Rest of Asia-Pacific)
5.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015-2025 (US$ Mn)

 

Chapter 6 Company Profiles


6.1 AstraZeneca plc
6.2 Intercept Pharmaceutical Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA
6.5 Allergan
6.6 Gilead Science Inc.
6.7 Zydus Cadila
6.8 Immuron Ltd.
6.9 Conatus Pharmaceuticals
6.10 Novo Nordisk
6.11 Enzo Biochem, Inc.
6.12 Raptor Pharmaceuticals 

TABLE 1 Global Non-Alcoholic Steatohepatitis Market, By Drug Type (US$ Mn), 2015– 2025
(Value)
TABLE 2 Global Non-Alcoholic Steatohepatitis Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 4 North America Non-Alcoholic Steatohepatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Non-Alcoholic Steatohepatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 8 Asia - Pacific Non-Alcoholic Steatohepatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Non-Alcoholic Steatohepatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015 – 2025
(US$ Mn)
TABLE 12 Middle East and Africa Non-Alcoholic Steatohepatitis Market, by Country, 2015 – 2025
(US$ Mn)
TABLE 13 AstraZeneca plc: Company Snapshot (Business Description; Financial Performance;
Product Position/Portfolio; News Coverage)
TABLE 14 Intercept Pharmaceutical Inc.: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 15 Galmed Pharmaceuticals: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 16 GENFIT SA: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 17 Allergan: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 18 Gilead Science Inc.: Company Snapshot (Business Description; Financial Performance;
Product Position/Portfolio; News Coverage)
TABLE 19 Zydus Cadila: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 20 Immuron Ltd.: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 21 Conatus Pharmaceuticals: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 22 Novo Nordisk: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 23 Enzo Biochem, Inc.: Company Snapshot (Business Description; Financial Performance;
Product Position/Portfolio; News Coverage)
TABLE 24 Raptor Pharmaceuticals: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)

FIG. 1 Non-Alcoholic Steatohepatitis Market: Research Methodology
FIG. 2 Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016 (US$ Mn)
FIG. 3 Non-Alcoholic Steatohepatitis Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition
FIG. 5 Competitive Analysis: Global Alpha Mannosidosis Market, 2016 (Value %)
FIG. 6 Global Obeticholic Acid Market(US$ Mn), 2015-2025
FIG. 7 Global Aramchol Market(US$ Mn), 2015-2025
FIG. 8 Global Saroglitazar Market (US$ Mn), 2015-2025
FIG. 9 Global Elafibranor Market (US$ Mn), 2015-2025

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)